DSpace logo

Use este identificador para citar ou linkar para este item: http://repositorioinstitucional.uea.edu.br//handle/riuea/4123
Registro completo de metadados
Campo DCValorIdioma
dc.contributor.authorBelota, Rosa Cristina Caldas-
dc.date.available2022-08-10-
dc.date.available2022-08-11T16:59:20Z-
dc.date.issued2020-03-16-
dc.identifier.urihttp://repositorioinstitucional.uea.edu.br//handle/riuea/4123-
dc.description.abstractHepatitis B is an infectious disease of worldwide importance and of great interest for transfusion medicine. The Amazon region has areas of high endemicity, outlining a worrying scenario for local transfusion safety. However, results profiles in serological and molecular screening make us question whether they are associated with infection by the hepatitis B virus. The present study is justified by the need to verify whether results profiles in screening for hepatitis B present or not detectable viral load and its possible impact on public health and stocks of blood components. Objective: To investigate the prevalence of Hepatitis B in blood donors from the blood center of Amazonas (HEMOAM) according to the reactivity for NAT-HBV, HBsAg, Anti-HBc and viral load in the period from January 2015 to December 2018. Material and Methods: Descriptive, retrospective study of HEMOAM donor records with positive results and their correspondence with the results of viral load obtained through the electronic medical record system of the Tropical Medicine Foundation Dr. Heitor Vieira Dourado (FMT-HVD). Results: 230,591 blood donations were analyzed, of which 3,932 (1.7%) were retained in serological and molecular screening with 3,104 (1.34%) of the retentions showing the following results NAT HBV: 3.02%; HBsAg: 9.92% and Anti-HBc: 93.8%. Among the reactive donors, 314 (10.11%) had a forwarding profile for the detection of viral load in the FMT-HVD, however the records of only 73 (23.1%) were found, of which 95.8% with the profile: NAT HBV positive / HBsAg positive / Anti-HBC positive and 100% with the profile: NAT HBV negative / HBsAg positive / Anti-HBC positive had detectable viral load whereas 100% of donors with only HBsAg positive did not show viral load. Conclusion: In this study it was possible to verify the importance of the need for traceability of blood donors forwarded for the detection of viral charge in the reference center, because despite a considerable amount of reactive donors, to demonstrate the importance of hepatitis B in the state of Amazonas, unexpected results were observed regarding the presence or absence of viral load in certain reactivity profiles in serological and molecular screening, which may be impacting both the stocks of blood components and public health with the detection of new cases of asymptomatic hepatitis Bpt_BR
dc.languageporpt_BR
dc.publisherUniversidade do Estado do Amazonaspt_BR
dc.rightsAcesso Abertopt_BR
dc.subjectHBsAgpt_BR
dc.subjectAnti-HBcpt_BR
dc.subjectNAT HBVpt_BR
dc.subjectHepatite Bpt_BR
dc.subjectVHBpt_BR
dc.titleTriagem da hepatite B em doadores de sangue no Estado do Amazonaspt_BR
dc.title.alternativeHepatitis B screening in blood donors in the State of Amazonaspt_BR
dc.typeDissertaçãopt_BR
dc.date.accessioned2022-08-11T16:59:20Z-
dc.contributor.advisor1Albuquerque, Sérgio Roberto Lopes-
dc.contributor.advisor1Latteshttp://lattes.cnpq.br/7446141046261325pt_BR
dc.contributor.referee1Costa, Allysom Guimarães da-
dc.contributor.referee1Latteshttp://lattes.cnpq.br/7531662673281014pt_BR
dc.contributor.referee2Passos, Leny Nascimento da Motta-
dc.contributor.referee2Latteshttp://lattes.cnpq.br/8194622149198642pt_BR
dc.contributor.referee3Castilho, Marcia da Costa-
dc.contributor.referee3Latteshttp://lattes.cnpq.br/2945789466069728pt_BR
dc.creator.Latteshttp://lattes.cnpq.br/6082907606613527pt_BR
dc.description.resumoA hepatite B é uma doença infecciosa de importância mundial e de grande interesse para a medicina transfusional. A região Amazônica possui áreas de elevada endemicidade, delineando um cenário preocupante para a segurança transfusional local. No entanto, perfis de resultados na triagem sorológica e molecular, nos fazem questionar se os mesmos estão associados a infecção pelo vírus da hepatite B. O presente estudo justifica-se pela necessidade de verificar se perfis de resultados na triagem da hepatite B apresentam ou não carga viral detectável e seu possível impacto na saúde pública e nos estoques de hemocomponentes. Objetivo: Investigar a prevalência de Hepatite B em doadores de sangue do Hemocentro do Amazonas (HEMOAM) segundo a reatividade para NAT-HBV, HBsAg, Anti-HBc e carga viral no período de janeiro de 2015 a dezembro de 2018. Material e Métodos: Estudo descritivo, retrospectivo dos registros de doadores do HEMOAM com resultados positivos e sua correspondência com os resultados de carga viral adquiridos através do sistema de prontuários eletrônicos da Fundação de Medicina Tropical Dr. Heitor Vieira Dourado (FMT-HVD). Resultados: Foram analisadas 230.591 doações de sangue, das quais 3.932 (1,7%) foram retidas na triagem sorológicae molecular com3.104 (1,34%) das retenções apresentando os seguintes resultados NAT HBV: 3,02%; HBsAg: 9,92% e Anti- HBc: 93,8%. Dentre os doadores reativos, 314 (10,11%) possuíam perfil de encaminhamento para a detecção de carga viral no FMT-HVD, no entanto foram encontrados os registros de apenas 73 (23,1%), dos quais 95,8% com o perfil: NAT HBV positivo / HBsAg positivo / Anti-HBC positivo e 100% com o perfil: NAT HBV negativo / HBsAg positivo / Anti-HBC positivo possuíam carga viral detectável, ao passo que 100% dos doadores apenas com HBsAg positivo não apresentaram carga viral. Conclusão: Neste estudo foi possível constatar a importância da necessidade da rastreabilidade dos doadores de sangue encaminhados para a detecção de carga viral no centro de referência, pois apesar de uma quantidade considerável de doadores reativos, demonstrando a importância da hepatite B no estado do Amazonas, foram observados resultados não esperados quanto a presença ou não de carga viral em determinados perfis de reatividade na triagem sorológica e molecular o que pode estar impactando tanto nos estoques de hemocomponentes, quanto na saúde pública com a detecção de novos casos de hepatite B assintomáticapt_BR
dc.publisher.countryBrasilpt_BR
dc.publisher.programPPGH -PROGRAMA DE PÓS-GRADUAÇÃO EM CIÊNCIAS APLICADAS À HEMATOLOGIApt_BR
dc.relation.references1. Organization WH. Global hepatitis report 2017. In: WHO, editor. Geneva2017. p. 11, 2. 2. Ye X, Li T, Xu X, Du P, Zeng J, Zhu W, et al. Characterisation and follow-up study of occult hepatitis B virus infection in anti-HBc-positive qualified blood donors in southern China. Blood transfusion = Trasfusione del sangue. 2017;15(1):6-12. 3. Makvandi M. Update on occult hepatitis B virus infection. World journal of gastroenterology. 2016;22(39):8720-34. 4. Brasil. Boletim epidemiológico - Hepatites virais. In: Saúde Md, editor. Brasília2018. 5. Souto FJ. Distribution of hepatitis B infection in Brazil: the epidemiological situation at the beginning of the 21 st century. Revista da Sociedade Brasileira de Medicina Tropical. 2016;49(1):11-23. 6. DECRETO Nº 95.721. , Regulamenta a Lei nº 7.649, de 25 de janeiro de 1988, que "estabelece a obrigatoriedade do cadastramento dos doadores de sangue bem como a realização de exames laboratoriais no sangue coletado, visando a prevenir a propagação de doença". (1988). 7. PORTARIA DE CONSOLIDAÇÃO Nº 5, DE 28 DE SETEMBRO DE 2017, (2017). 8. Candotti D, Boizeau L, Laperche S. Occult hepatitis B infection and transfusion- transmission risk. Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine. 2017;24(3):189-95. 9. Fonseca JC. History of viral hepatitis. Revista da Sociedade Brasileira de Medicina Tropical. 2010;43(3):322-30. 10. Dane DS, Cameron CH, Briggs M. Virus-like particles in serum of patients with Australia-antigen-associated hepatitis. Lancet. 1970;1(7649):695-8. 11. Lamontagne RJ, Bagga S, Bouchard MJ. Hepatitis B virus molecular biology and pathogenesis. Hepatoma research. 2016; 2:163-86. 12. Lu FM, Wang J, Chen XM, Jiang JN, Zhang WH, Zhao JM, et al. [The potential use of serum HBV RNA to guide the functional cure of chronic hepatitis B]. Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology. 2017;25(2):105- 10. 13. Venkatakrishnan B, Zlotnick A. The Structural Biology of Hepatitis B Virus: Form and Function. Annual review of virology. 2016;3(1):429-51. 14. Perkins JADe. Medical and Scientific Illustrations. In: diseases I, editor. 2002. 15. Diab A, Foca A, Zoulim F, Durantel D, Andrisani O. The diverse functions of the hepatitis B core/capsid protein (HBc) in the viral life cycle: Implications for the development of HBc-targeting antivirals. Antiviral research. 2018;149:211-20. 16. Karayiannis P. Hepatitis B virus: virology, molecular biology, life cycle and intrahepatic spread. Hepatology international. 2017;11(6):500-8. 17. Hu J, Liu K. Complete and Incomplete Hepatitis B Virus Particles: Formation, Function, and Application. Viruses. 2017;9(3). 18. Gerlich WH. Medical virology of hepatitis B: how it began and where we are now. Virology journal. 2013;10:239. 19. Yuen MF, Chen D, Dusheiko GM, Janssen HLA, Lau DTY, Locarnini SA, et al. Hepatitis B virus infection. Nature reviews Disease primers. 2018;4:18036. Folha: 81 60 20. Sandhu P, Haque M, Humphries-Bickley T, Ravi S, Song J. Hepatitis B Virus Immunopathology, Model Systems, and Current Therapies. Frontiers in immunology. 2017;8:436. 21. Song JE, Kim DY. Diagnosis of hepatitis B. Annals of translational medicine. 2016;4(18):338. 22. Seto WK, Yuen MF. Viral hepatitis: 'Immune tolerance' in HBV infection: danger lurks. Nature reviews Gastroenterology & hepatology. 2016;13(11):627-8. 23. Brasil. Manual técnico para diagnóstico das hepatites virais. In: Departamento de Vigilância PeCdIST, do HIV/Aids e das Hepatites Virais, editor. 2a ed. Brasília2018. 24. Shi YH. Correlation between hepatitis B virus genotypes and clinical outcomes. Japanese journal of infectious diseases. 2012;65(6):476-82. 25. Sunbul M. Hepatitis B virus genotypes: global distribution and clinical importance. World journal of gastroenterology. 2014;20(18):5427-34. 26. MacLachlan JH, Cowie BC. Hepatitis B virus epidemiology. Cold Spring Harbor perspectives in medicine. 2015;5(5):a021410. 27. Lampe E, Mello FCA, do Espirito-Santo MP, Oliveira CMC, Bertolini DA, Goncales NSL, et al. Nationwide overview of the distribution of hepatitis B virus genotypes in Brazil: a 1000-sample multicentre study. The Journal of general virology. 2017;98(6):1389-98. 28. Mello FC, Araujo OC, Lago BV, Motta-Castro AR, Moraes MT, Gomes SA, et al. Phylogeography and evolutionary history of hepatitis B virus genotype F in Brazil. Virology journal. 2013;10:236. 29. Crispim MA, Fraiji NA, Campello SC, Schriefer NA, Stefani MM, Kiesslich D. Molecular epidemiology of hepatitis B and hepatitis delta viruses circulating in the Western Amazon region, North Brazil. BMC infectious diseases. 2014;14:94. 30. Esposito A, Sabia C, Iannone C, Nicoletti GF, Sommese L, Napoli C. Occult Hepatitis Infection in Transfusion Medicine: Screening Policy and Assessment of Current Use of Anti- HBc Testing. Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie. 2017;44(4):263-72. 31. Control CfD. Hepatitis B. Yellow Book. 2018. p. Map prevalence of hepatitis B virus infection. 32. Ximenes RA, Figueiredo GM, Cardoso MR, Stein AT, Moreira RC, Coral G, et al. Population-Based Multicentric Survey of Hepatitis B Infection and Risk Factors in the North, South, and Southeast Regions of Brazil, 10-20 Years After the Beginning of Vaccination. The American journal of tropical medicine and hygiene. 2015;93(6):1341-8. 33. Saúde Md. Boletim epidemiológico das hepatites virais. In: Saúde SdVe, editor. 2019. 34. Braga WS, Brasil LM, de Souza RA, Castilho Mda C, da Fonseca JC. The occurrence of hepatitis B and delta virus infection within seven Amerindian ethnic groups in the Brazilian western Amazon. Revista da Sociedade Brasileira de Medicina Tropical. 2001;34(4):349-55. 35. Braga WS, Castilho Mda C, Borges FG, Martinho AC, Rodrigues IS, Azevedo EP, et al. Prevalence of hepatitis B virus infection and carriage after nineteen years of vaccination program in the Western Brazilian Amazon. Revista da Sociedade Brasileira de Medicina Tropical. 2012;45(1):13-7. 36. Candotti D, Laperche S. Hepatitis B Virus Blood Screening: Need for Reappraisal of Blood Safety Measures? Frontiers in medicine. 2018;5:29. 37. Stasi C, Silvestri C, Voller F. Emerging Trends in Epidemiology of Hepatitis B Virus Infection. Journal of clinical and translational hepatology. 2017;5(3):272-6. 38. Castilho Mda C, Oliveira CM, Gimaque JB, Leao JD, Braga WS. Epidemiology and molecular characterization of hepatitis B virus infection in isolated villages in the Western Brazilian Amazon. The American journal of tropical medicine and hygiene. 2012;87(4):768- 74. Folha: 82 61 39. Li L, Han T, Zang L, Niu L, Cheng W, Lin H, et al. The current incidence, prevalence, and residual risk of hepatitis B viral infections among voluntary blood donors in China. BMC infectious diseases. 2017;17(1):754. 40. Siraj N, Achila OO, Issac J, Menghisteab E, Hailemariam M, Hagos S, et al. Seroprevalence of transfusion-transmissible infections among blood donors at National Blood Transfusion Service, Eritrea: a seven-year retrospective study. BMC infectious diseases. 2018;18(1):264. 41. de Almeida-Neto C, Sabino EC, Liu J, Blatyta PF, Mendrone-Junior A, Salles NA, et al. Prevalence of serologic markers for hepatitis B and C viruses in Brazilian blood donors and incidence and residual risk of transfusion transmission of hepatitis C virus. Transfusion. 2013;53(4):827-34. 42. Lima Verde RMC, Santos DN, Mota FML, Soares FL, Nascimento HM, Oliveira EH. Prevalence of hepatitis b in blood donors at the coordinating blood center of the state of Piauí, Brazil. International Journal of Development Research. 2018;08( 04):20122-7. 43. Brasil. 7° Boletim de produção hemoterápica. Hemoprod 2018. In: Sanitária. ANdV, editor. 2020. 44. Souza M, Abrahim C, Souza R, Campos C, Pinheiro F, Salgueiro J, et al. Descarte de sangue e componentes pela triagem das doenças transmissíveis pelo sangue nas doações captadas no hemocentro do amazonaS (HEMOAM). In: ABHH ABdHeH-, editor.: ABHH; 2016. 45. Monich AG, Dantas TW, Favero KB, Almeida PTR, Maluf EC, Capeletto CM, et al. Blood discard rate in a blood center in Curitiba - Brazil. Ten years of study. Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis. 2017;56(2):130-4. 46. Saber HR, Tabatabaee SM, Abasian A, Jamali M, SalekMoghadam E, Hajibeigi B, et al. Incidence and Residual Risk of HIV, HBV and HCV Infections Among Blood Donors in Tehran. Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion. 2017;33(3):412-6. 47. O'Brien SF, Yi QL, Fan W, Scalia V, Goldman M, Fearon MA. Residual risk of HIV, HCV and HBV in Canada. Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis. 2017;56(3):389-91. 48. Moresco MdS, Virgolino HdA, Morais Md, Motta‐Passos Id, Gomes‐Gouvêa M, Assis Ld, et al. Occult hepatitis B virus infection among blood donors from the Brazilian Amazon: implications for transfusion policy. Vox sanguinis. 2014;107(1):19-25. 49. Wang Q, Klenerman P, Semmo N. Significance of anti-HBc alone serological status in clinical practice. The lancet Gastroenterology & hepatology. 2017;2(2):123-34. 50. Lin H, Zhao H, Tang X, Hu W, Jiang N, Zhu S, et al. Serological Patterns and Molecular Characterization of Occult Hepatitis B Virus Infection among Blood Donors. Hepatitis monthly. 2016;16(10):e40492. 51. Karimi G, Zadsar M, Vafaei N, Sharifi Z, FalahTafti M. Prevalence of antibody to Hepatitis B core antigen and Hepatitis B virus DNA in HBsAg negative healthy blood donors. Virology journal. 2016;13:36. 52. Muselmani W, Habbal W, Monem F. Significance of screening antibodies to hepatitis B virus core antigen among Syrian blood donors. Transfusion medicine. 2013;23(4):265-8. 53. O'Flaherty N, Ushiro-Lumb I, Pomeroy L, Ijaz S, Boland F, De Gascun C, et al. Transfusion-transmitted hepatitis B virus (HBV) infection from an individual-donation nucleic acid (ID-NAT) non-reactive donor. Vox sanguinis. 2018;113(3):300-3. Folha: 83 62 54. Martin LA, Stramer SL, Kuhns MC, Schlauder GG. Correlation of improved hepatitis B surface antigen detection limits with hepatitis B virus DNA nucleic acid test yield in blood donations. Transfusion. 2012;52(10):2201-8. 55. Jahan M, Islam MA, Akbar SMF, Takahashi K, Tabassum S, Rahman A, et al. Anti- HBc Screening of Blood Donors in Bangladesh: Relevance to Containment of HBV Propagation. Journal of clinical and experimental hepatology. 2016;6(2):115-8. 56. Safic Stanic H, Babic I, Maslovic M, Dogic V, Bingulac-Popovic J, Miletic M, et al. Three-Year Experience in NAT Screening of Blood Donors for Transfusion Transmitted Viruses in Croatia. Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie. 2017;44(6):415-20. 57. Almeida RW, Mello F, Menegoy IV, Santo M, Ginuino CF, Sousa PSF, et al. Detection and molecular characterisation of a diagnosis escape variant associated with occult hepatitis B virus in Brazil. Memorias do Instituto Oswaldo Cruz. 2017;112(7):485-91. 58. Spreafico M, Berzuini A, Foglieni B, Candotti D, Raffaele L, Guarnori I, et al. Poor efficacy of nucleic acid testing in identifying occult HBV infection and consequences for safety of blood supply in Italy. Journal of hepatology. 2015;63(5):1068-76. 59. Vermeulen M, van Drimmelen H, Coleman C, Mitchel J, Reddy R, Lelie N. A mathematical approach to estimate the efficacy of individual-donation and minipool nucleic acid amplification test options in preventing transmission risk by window period and occult hepatitis B virus infections. Transfusion. 2014;54(10):2496-504. 60. Vermeulen M, Dickens C, Lelie N, Walker E, Coleman C, Keyter M, et al. Hepatitis B virus transmission by blood transfusion during 4 years of individual-donation nucleic acid testing in South Africa: estimated and observed window period risk. Transfusion. 2012;52(4):880-92. 61. Lelie N, Bruhn R, Busch M, Vermeulen M, Tsoi WC, Kleinman S, et al. Detection of different categories of hepatitis B virus (HBV) infection in a multi-regional study comparing the clinical sensitivity of hepatitis B surface antigen and HBV-DNA testing. Transfusion. 2017;57(1):24-35. 62. Santos FO, Vieira JFF, Leite GR, Pelazza BB, Maia LG, MA. M. Blood bags and disposal and positivity serological on donors in a blood center. . JNurs. 2016;10(9):3223-31. 63. Kim W. Epidemiology of hepatitis B in the United States. Hepatology. 2009;49(5):28- 34. 64. Motté MO, Lopes ACS, Mello CL, Renon TF, Carneiro RC, Freitas NA. SOROPREVALÊNCIA DE INFECÇÃO PELOS VÍRUS DAS HEPATITES B E C EM DOADORES DE SANGUE DO NORTE FLUMINENSE. Revista Científica FMC. 2018;13(1). 65. James AB, Hillyer CD, BH. S. Demographic differences in estimated blood donor eligibility prevalence in the United States. Transfusion. 2011;52(5):1050-61. 66. JL; N-S, Schiavon L, Carvalho-Filho R, Takemi E, Akio M, Orlando BJ ea. Clinical and epidemiological profile of female blood donors with positive serology for viral hepatitis B. . Rev SocBras Med Trop. 2015;48(5):524-31. 67. Tigabu A, Engda T, Mekonnen F. Seroprevalence of transfusion transmissible viral infections (HIV, HBV and HCV) among voluntary blood donors at University of Gondar Comprehensive Specialized Hospital, Gondar; Northwest Ethiopia. . BMC InfectDis 2019;19:393. 68. Gao Z, Zhang Y, Shan H, Shi L, Liu J, Xu M, et al. A 30-year systematic review and meta-analysis of hepatitis B virus among blood donors in mainland China: revealing increase of new threats. Transfusion. 2017;57(8):1988-97. 69. Jaques B, Saldanha PCdA, Moraes ACRd. Profile of blood donations with a positive serology in Southern Brazil. Hematology, Transfusion and Cell Therapy. 2019. Folha: 84 63 70. Khazaei S, Karami M, Ayubi E, Mohammadbeigi A, Hasanbeigi A, Mansori K, et al. Trends in epidemiology of Hepatitis B and C Infections in Ilam Province: National Notifiable Diseases Surveillance System data. Caspian journal of internal medicine. 2018;9(1):16-21. 71. Silva MJ, Valente J, Capela T, Russo P, Calinas F. Epidemiology of hepatitis B in Portugal. European journal of gastroenterology & hepatology. 2017;29(3):249-58. 72. Pereira V, Wolf JM, Luz C, Stumm GZ, Boeira TDR, Galvan J, et al. Risk factors for hepatitis B transmission in South Brazil. Memorias do Instituto Oswaldo Cruz. 2017;112(8):544-50. 73. Mohsenizadeh M, Mollaei HR, Ghaziizadeh M. Seroepidemiological Study of Hepatitis B, C and HIV among Blood Donors in Kerman. Asian Pacific journal of cancer prevention : APJCP. 2017;18(12):3267-72. 74. Yilmaz S, Unlu A, Cetinkaya RA, Yapar M, Avci IY, Yilmaz S, et al. A strategical re- thinking on National Blood Donor Pool: Anti-HBc positivity related re-entry mechanisms. Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis. 2016;54(2):271-5. 75. Jahan M, Islam MA, Akbar SM, Takahashi K, Tabassum S, Rahman A, et al. Anti- HBc Screening of Blood Donors in Bangladesh: Relevance to Containment of HBV Propagation. J Clin Exp Hepatol. 2016;6(2):115-8. 76. Houareau C, Offergeld R. Anti-HBc screening - is it worth the effort? Results of a 10- year surveillance programme covering more than 30 million donations in Germany. Vox sanguinis. 2019;114(5):459-66. 77. Dodd RY, Nguyen ML, Krysztof DE, Notari EP, Stramer SL. Blood donor testing for hepatitis B virus in the United States: is there a case for continuation of hepatitis B surface antigen detection? Transfusion. 2018;58(9):2166-70. 78. Kiely P, Hoad VC, Wood EM. False positive viral marker results in blood donors and their unintended consequences. Vox sanguinis. 2018. 79. Ponde RA. Atypical serological profiles in hepatitis B virus infection. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology. 2013;32(4):461-76pt_BR
dc.publisher.initialsUEApt_BR
Aparece nas coleções:DISSERTAÇÃO - PPCAH Programa de Pós-Graduação em Ciências Aplicadas à Hematologia

Arquivos associados a este item:
Arquivo Descrição TamanhoFormato 
Triagem da hepatite B em doadores de sangue no Estado do Amazonas.pdf2,5 MBAdobe PDFVisualizar/Abrir
Mostrar registro simples do item Visualizar estatísticas


Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.